

1-1 By: Carona, Deuell S.B. No. 730
1-2 (In the Senate - Filed February 16, 2007; March 6, 2007,
1-3 read first time and referred to Committee on State Affairs;
1-4 May 3, 2007, reported favorably by the following vote: Yeas 9,
1-5 Nays 0; May 3, 2007, sent to printer.)

1-6 A BILL TO BE ENTITLED
1-7 AN ACT

1-8 relating to a study concerning maximum lifetime benefit limits
1-9 under health benefit plan coverage applicable to
1-10 hemophilia-related services, supplies, pharmaceuticals, and
1-11 biologics.

1-12 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

1-13 SECTION 1. DEFINITION. In this Act, "department" means the
1-14 Texas Department of Insurance.

1-15 SECTION 2. STUDY. (a) The department shall conduct a
1-16 study of the maximum lifetime benefit limits under health benefit
1-17 plan coverage as those limits are applied to hemophilia-related
1-18 services, supplies, pharmaceuticals, and biologics.

1-19 (b) In conducting the study, the department shall consult
1-20 health benefit plan issuers, physicians, organizations
1-21 representing the interests of individuals with hemophilia, and the
1-22 office of public insurance counsel.

1-23 (c) The study must consider the manner in which
1-24 hemophilia-related services, supplies, pharmaceuticals, and
1-25 biologics are provided by the Texas Health Insurance Risk Pool.

1-26 SECTION 3. REPORT. Not later than September 1, 2008, the
1-27 department shall report the results of the study conducted under
1-28 this Act to the governor, the lieutenant governor, and the speaker
1-29 of the house of representatives. The report must include:

1-30 (1) the estimated cost for an enrollee of providing
1-31 coverage for hemophilia-related services, supplies,
1-32 pharmaceuticals, and biologics without a maximum lifetime benefit
1-33 limit or with an increased maximum lifetime benefit limit;

1-34 (2) a review of the benefits to enrollees of providing
1-35 coverage for hemophilia-related services, supplies,
1-36 pharmaceuticals, and biologics without a maximum lifetime benefit
1-37 limit or with an increased maximum lifetime benefit limit; and

1-38 (3) the recommendation of the commissioner of
1-39 insurance, if any, for legislation concerning the maximum lifetime
1-40 benefit limits under health benefit plan coverage as those limits
1-41 are applied to hemophilia-related services, supplies,
1-42 pharmaceuticals, and biologics.

1-43 SECTION 4. EXPIRATION. This Act expires June 1, 2009.

1-44 SECTION 5. EFFECTIVE DATE. This Act takes effect September
1-45 1, 2007.

1-46 * * * * *